Fed's Mester says the phrase 'considerable period' in Fed statement should be reformulated - CNBC
Gapping down In reaction to disappointing earnings/guidance: GTI -12.8%, AIR -3.6%, CPRT -2.9%, ACN -2.6%, PZZI -2.5%
Other news: ECTE -71.9% (suspends operations to conserve liquidity), ATOS -54.1% (announced that the FDA has issued a determination that the ForeCYTE Breast Aspirator is "not substantially equivalent" to its predicate device; not cleared for marketing in U.S.), NXTD -7.5% (pulling back modestly following recent surge), MMLP -5.1% (commenced public offering of 3 mln common units under its existing shelf registration statement), GLOP -3.8% (announced public offering of 4.5 mln common units), EVHC -3% (announced sale of 17,500,000 shares of stock by selling stockholders), LAND -2% (announced common stock offering of 1.15 mln shares)
Analyst comments: MS -0.6% (downgraded to Neutral from Overweight at JP Morgan), SDRL -0.6% (resumed with a Underperform at Wells Fargo)
Gapping up In reaction to strong earnings/guidance: ELMD +43.2%, NEWL +9.1%, BBBY +5.5%, SCS +4.3%, MTN +3.2%
M&A news: STRZA +5.7% (Starz considering sale although Fox (FOXA) is not interested, according to reports), ACOR +3.9% (to acquire Civitas Therapeutics for $525 mln in cash) Select metals/mining stocks trading higher: BHP +1%, AG +1%, NEM +0.9%, X +0.8%
Other news: RITT +36.3% (seeing continued strength), MACK +25.9% (co and Baxter (BAX) enter into exclusive ex-U.S. licensing agreement to develop and commercialize novel cancer compound MM-398), LPCN +16.7% (co to host a conference call to discuss top-line results from its Study of Oral Androgen Replacement pivotal Phase 3 clinical study), GDOT +6.3% (co's GoBank Checking Account launches exclusively at Walmart (WMT) ), MTL +6.2% (cont vol surrounding spec of co filing for bankruptcy), IMUC +5.6% (expands cancer immunotherapy platform with antigen-specific T-cell technology licensed from Caltech), ZSPH +5.1% (announced positive top-line results from HARMONIZE (ZS004), a second Phase 3 clinical trial of ZS-9 in patients with Hyperkalemia), AVNR +2.8% (prices 18.2 mln shares of its common stock at $11.00 per share), PLUG +2.6% (cont strength following co's reaffirm yesterday), SNY +2.1% (collaborates on gene therapy for rare disease that causes childhood blindness), GPRO +2% (cont vol pre-mkt trade), SCTY +1.8% (announced launch of a $500 mln convertible senior notes offering), TOT +1.8% (co's Energy Ventures is investing in NexSteppe startup), ALCS +1.7% (MFP Partners liquidated stake in the company), MU +1.3% (in discussions with Advanced Semi (ASX) to setup IC packaging and testing unit, according to reports), BABA +1.1% (cont vol following IPO), YPF +1.1% (Kyle Bass reveals stake in Argentine energy company YPF on CNBC)
Analyst comments: SRPT +4.1% (initiated with a Outperform at Credit Suisse), RIO +1.5% (upgraded to Overweight from Equal-Weight at Morgan Stanley), WGBS +1.1% (initiated with a Buy at Brean Capital), GLMD +1.1% (target raised to $24 at MLV & Co), OXY +1.1% (added to US 1 List at BofA/Merrill), AWAY +1% (initiated with a Buy at Sun Trust Rbsn Humphrey), HCLP +1% (upgraded to Buy from Hold at Wunderlich), ALV +0.9% (initiated with a Outperform at Exane BNP Paribas)
Gapping down: ECTE -72.8%, ATOS -52.8%, GTI -17.6%, NXTD -5.7%, MMLP -4.7%, GLOP -4.3%, AIR -3.5%, PZZI -2.5%, ACN -2.3%, EVHC -2.2%, LAND -2%, RBS -1.1%